Interchange Capital Partners’s Coherus Oncology CHRS Stock Holding History

Interchange Capital Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-38	Closed	–	–	380
2020 Q4	$0	Buy	+38	New	+$677	﹤0.01%	1195

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Interchange Capital Partners's CHRS Position: Q1 2021 in Review

Interchange Capital Partners sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 38 shares.

Interchange Capital Partners first reported a position in CHRS in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

Interchange Capital Partners reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
Interchange Capital Partners sold 38 Coherus Oncology shares in Q1 2021.
Interchange Capital Partners first reported a position in Coherus Oncology in Q4 2020 and held it in 1 quarter.
Interchange Capital Partners's Coherus Oncology position peaked at $0 in Q4 2020.
205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.